Hifumi Crossover Pro, Democratizing Unlisted Investment, Surpasses 50 Billion Yen in Net Assets, Becoming Japan's Largest Crossover Fund!

SBI Capital Management Co., Ltd. (hereinafter 'our company'), an SBI Group company that operates the 'Hifumi' series of investment trusts, announces that the net asset value of 'Hifumi Crossover Pro,' which invests in unlisted and listed companies and was launched in September 2024, surpassed 50 billion yen on April 8, 2026. As a public investment trust that conducts 'crossover investment' by investing in unlisted companies expected to go public and holding shares even after listing, 'Hifumi Crossover Pro' is the largest in Japan in terms of net asset value (※1). As of April 14, 2026, the net asset value per share was 13,711 yen.

Innovacell Inc. (※2), an unlisted company invested in by 'Hifumi Crossover Pro,' was listed on the Tokyo Stock Exchange Growth Market on February 24, 2026. This marks the first instance of an unlisted investment in 'Hifumi Crossover Pro' leading to a public listing (1st case). Innovacell Inc. is a company engaged in the development and manufacturing of regenerative medicine products for fecal incontinence and urinary incontinence.

※1: Researched by our company (as of April 14, 2026) ※2: This does not constitute a recommendation for individual stocks.

Recent Holding Trend (Top 10 Holdings, as of March 31, 2026) ※ Ratios indicate the effective proportion to the net asset value of Hifumi Crossover Pro. Unlisted stocks are excluded.

About 'Hifumi Crossover Pro' 'Hifumi Crossover Pro' is an investment trust that invests in both unlisted and listed companies, engaging in crossover investment that transcends the framework of 'listing.' This fund was launched in September 2024 as a public investment trust that allows investment in both unlisted and listed stocks through NISA.

While expanding opportunities for unlisted investment, which has traditionally been concentrated among a limited number of investors, to the general public, it directly addresses structural challenges faced by Japanese startups such as 'difficulty in fundraising before listing' and 'a decrease in long-term shareholders after listing,' aiming for a new form of investment that consistently supports growth from the early to mature stages. With its net asset value surpassing 50 billion yen as of April 8, 2026, it has gained trust and support from many investors.

'Hifumi Crossover Pro' can be purchased through our direct sales account or from sales partners. Please refer to the following for the latest list of sales companies: https://hifumi.rheos.jp/fund/crossover/about/?tab0=2#hf-distributor

Monthly operation reports for 'Hifumi Crossover Pro' can be viewed here: https://hifumi.rheos.jp/fund/crossover/report/

About Rheos Capital Works Co., Ltd. Rheos Capital Works was founded in 2003 with the management philosophy 'Contribute to society through the capital markets.' The investment trusts 'Hifumi' series, which we manage and sell, support customers' long-term asset formation through 'growing while protecting' investment. In our investment advisory business, we manage assets entrusted by corporate pension funds and institutional investors both domestically and internationally. Rheos Capital Works is a group company of SBI Global Asset Management Co., Ltd. (Securities Code 4765). URL: https://www.rheos.jp/

Fees and risks associated with investment trusts: https://www.rheos.jp/policy/risk/ Financial Instruments Business Operator: Kanto Local Finance Bureau Director (Kinsho) No. 1151 Member of the Investment Trusts Association of Japan

Note: This press release is for public disclosure of our services and achievements and is not intended for investment solicitation.